fertiShare Evaluation
NCT06587360
Recruiting
Sharing bad news (SBN) is a daily challenge for fertility staff and patients. Bad news happens at all stages of fertility care and includes e.g., diagnosing infertility, reporting unexpected, repeated, or definitive treatment failure. Extensive evidence shows that SBN triggers stress in staff due to anticipation of negative emotions and evaluations or, in extreme cases, even complaints and lawsuits. Inability to manage bad news can increase negative emotions in patients and fuel distrust, potent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle, Newcastle upon Tyne +4 locations
Conditions: Infertility Assisted Reproductive Technology
Register for Updates
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036
Recruiting
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California +156 locations
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +117 locations
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
NCT06222034
Recruiting
A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
07/24/2025
Locations: CHU Amiens - Hopital Nord, Amiens Cedex 1, Not set +8 locations
Conditions: Juvenile Idiopathic Arthritis
Register for Updates
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations
Conditions: Breast Neoplasms
Register for Updates
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
NCT04020055
Recruiting
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Emory University, Atlanta, Georgia +14 locations
Conditions: Fabry Disease
Register for Updates
Vitaccess Real MG Registry
NCT06064461
Recruiting
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records. Patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: UCI Health, Orange, California +7 locations
Conditions: Myasthenia Gravis
Register for Updates
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
NCT02543905
Recruiting
Prostate cancer is now the most common cancer in men in the Western world. In the United Kingdom (UK), there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8. Prostate cancer (PrCa) can run in some families and research studies have identified several genetic changes in Caucasian populations that are thought to increase the risk of developing prostate cancer. Other studies have shown that men from certain ethnic groups also have a higher risk of prostate cancer, an... Read More
Gender:
MALE
Ages:
Between 40 years and 69 years
Trial Updated:
07/24/2025
Locations: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey
Conditions: Prostate Cancer, Prostate Biopsy, Genetic Counselling, Genetic Markers
Register for Updates
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
NCT06045910
Recruiting
This is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in participants with B-cell malignancies post CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Dif... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/24/2025
Locations: University Hospital Birmingham NHS Foundation Trust, Birmingham, Not set +6 locations
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Lymphoma, B-Cell, Large B-cell Lymphoma
Register for Updates
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions
NCT06638541
Recruiting
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The Christie NHS Foundation Trust, Manchester, Not set +1 locations
Conditions: Prostate Cancer
Register for Updates
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371
Recruiting
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Orange County Research Center, Lake Forest, California +10 locations
Conditions: Asthma
Register for Updates
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110), San Francisco, California +83 locations
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates